Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FES
REST API REST API
Homo sapiens
FES is differentially expressed in 215 experiments: 73 organism parts: kidney, lung, ... (71 more);, 177 disease states: normal, glioblastoma, ... (175 more);, 84 cell types 264 cell lines 31 compound treatments and 69 other conditions.
Synonyms FPS
Orthologs Fes (Rattus norvegicus)   Q5E9H3_BOVIN (Bos taurus)   fes (Danio rerio)   Fes (Mus musculus)   ENSCING00000008978 (Ciona intestinalis)   FES (Gallus gallus)   Fps85D (Drosophila melanogaster)   fes (Xenopus laevis)   Q2YF50_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term regulation of cell shape, focal adhesion, cytosol, phosphatidylinositol binding, plasma membrane, regulation of cell adhesion, protein binding, cytoplasm, cell proliferation, regulation of cell proliferation, peptidyl-tyrosine phosphorylation, Golgi apparatus, lipid binding, microtubule cytoskeleton, protein tyrosine kinase activity, cell junction, ATP binding, axon guidance, multicellular organismal development, positive regulation of microtubule polymerization, regulation of cell differentiation, cytoplasmic membrane-bounded vesicle, nucleotide binding, protein serine/threonine kinase activity, cytoplasmic vesicle, non-membrane spanning protein tyrosine kinase activity, protein kinase activity, positive regulation of neuron projection development, positive regulation of myeloid cell differentiation, regulation of mast cell degranulation, regulation of vesicle-mediated transport, extrinsic to internal side of plasma membrane, protein autophosphorylation, protein phosphorylation, regulation of cell motility, positive regulation of actin cytoskeleton reorganization, immunoglobulin receptor binding
InterPro Term SH2, Prot_kinase_cat_dom, FCH, Tyr_kinase_non-rcpt_Fes_subgr, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession P07332, Q4JFK7, C9J3W6, E7EMJ7, E7ENM8, E9PGC7, E9PIJ7
Search EB-eye ENSG00000182511
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-AFMX-5, E-GEOD-22541, E-MEXP-1251, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (30 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
A549
1
2
E-GEOD-6013, E-GEOD-3202
SW480
2
E-GEOD-18005, E-MEXP-1014
Jurkat
1
2
E-MEXP-2197, E-GEOD-1880, E-MTAB-62
RPMI6666
1
E-MTAB-37
SNU1
1
E-GEOD-15460
258 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-20677, ... (44 experiments)

Factor Value U/D Experiments
CD34+
2
E-TABM-145, E-AFMX-5
mononuclear cell
2
E-GEOD-6053, E-MEXP-66
neutrophil
1
2
E-GEOD-3982, E-GEOD-995, E-GEOD-12662
CD8+ T cell
1
E-TABM-145
alveolar space neutrophil
1
E-GEOD-2322
activated B-cell
1
E-MEXP-2360
78 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-22529, E-GEOD-9692, E-GEOD-20602, E-MTAB-62, ... (43 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
AIDS-KS, HIV+, nodular (late) stage
2
E-MEXP-66, E-MTAB-62
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
cervical carcinoma
2
E-MTAB-62, E-MEXP-1331
chronic myelogenous leukemia
2
E-MTAB-62, E-GEOD-5550
171 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-15205, E-TABM-782, E-GEOD-697, E-GEOD-3720, ... (24 experiments)

Factor Value U/D Experiments
interferon-gamma + lipopolysaccharide
2
E-GEOD-5099, E-GEOD-7307
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
TNF
1
E-GEOD-15205
saline
1
E-GEOD-3026
BCR/ABL1
1
E-GEOD-15811
PGE2
1
E-MEXP-1230
25 more value(s).


Biosource provider

studied in E-MTAB-37

Factor Value U/D Experiments
ECACC
1
E-MTAB-37
DSMZ
1
E-MTAB-37


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-2171, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-1140, E-MEXP-1251, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-MEXP-2359, E-GEOD-6236, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-22541, E-TABM-147, E-GEOD-21138 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578, E-GEOD-6431

Genotype
studied in E-TABM-1029, E-TABM-321, E-GEOD-20115, E-TABM-868, E-GEOD-18005, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-GEOD-22278, E-MEXP-2146

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-TABM-666, E-GEOD-6919, ... (20 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561, E-GEOD-980

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-MEXP-1403

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19246

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-101, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-18995

Stimulation
studied in E-GEOD-20114, E-GEOD-23984

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Tissue
studied in E-GEOD-30573

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19815, E-GEOD-12198

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541

Tumor size
studied in E-GEOD-6532

Processing time: 0.45 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM